All questions
Clinical trials: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination 13 questions · 2 sources
Clinical trials questions that apply to every indication of Gardasil 9 are on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications: Clinical trials .
Study results Gardasil 9 vs Gardasil in women 16-26: efficacy against HPV 31-58 disease? Applies to Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)
“Table 7: Analysis of Efficacy of GARDASIL 9 against HPV Types 31, 33, 45, 52, and 58 in the PPE* Population of 16-
through 26-Year-old Girls and Women (Study 1)
Disease Endpoint
GARDASIL 9
N† =7099
GARDASIL
N† =7105
GARDASIL 9
Efficacy
%
(95% CI)
n‡
Number of
cases
n‡
Number of
cases
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3, AIS, Cervical
Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal
Cancer
6016
1
6017
30
96.7
(80.9, 99.8)
HPV 31-, 33-, 45-, 52-, 58-related CIN 1
5948
1
5943
69
98.6
(92.4, 99.9)
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AIS
5948
1
5943
27
96.3
(79.5, 99.8)
HPV 31-, 33-, 45-, 52-, 58-related Vulvar or Vaginal Disease
6009
1
6012
16
93.8
(61.5, 99.7)” (opens the source at this quote in a new tab) Copy Flag
Did Gardasil 9 reduce HPV 31-58-related Pap abnormalities and procedures vs Gardasil? Applies to Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)
“GARDASIL 9 prevented HPV 31-, 33-, 45-, 52-, and 58-related persistent infection and disease and
also reduced the incidence of HPV 31-, 33-, 45-, 52-, and 58-related Pap test abnormalities, cervical and
external genital biopsy, and definitive therapy (Table 7).” (opens the source at this quote in a new tab) Copy Flag
“HPV 31-, 33-, 45-, 52-, 58-related ASC-US HR-HPV Positive
or Worse Pap# Abnormality
5881
35
5882
462
92.6
(89.7, 94.8)
HPV 31-, 33-, 45-, 52-, 58-related Biopsy
6016
7
6017
222
96.9
(93.6, 98.6)
HPV 31-, 33-, 45-, 52-, 58-related Definitive TherapyÞ
6012
4
6014
32
87.5
(65.7, 96.0)” (opens the source at this quote in a new tab) Copy Flag
Gardasil 9 vs Gardasil: were antibody responses to HPV 6, 11, 16, 18 non-inferior? Applies to Girls 9 through 15 years of age (Study 3) and girls and women 16 through 26 years of age (Study 1), Gardasil 9 compared with Gardasil
How was Gardasil 9 effectiveness inferred in children 9 to 15? Applies to Girls and boys 9 through 15 years of age
How was 2-dose Gardasil 9 effectiveness inferred in ages 9 to 14? Applies to Girls and boys 9 through 14 years of age given the 2-dose regimen (Study 8)
“Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in
9- through 14-year-old girls and boys who received a 2-dose regimen was inferred from non-inferiority
comparison conducted in the PPI population in Study 8 of GMTs following vaccination with GARDASIL 9
among 9- through 14-year-old girls and boys who received a 2-dose regimen (at 0, 6 months or 0, 12
months) with those among 16- through 26-year-old girls and women who received a 3-dose regimen (at
0, 2, 6 months). Anti-HPV GMTs at one month after the last dose among 9- through 14-year-old girls and
boys who received 2 doses of GARDASIL 9 were non-inferior to anti-HPV GMTs among 16- through 26-
year-old girls and women who received 3 doses of GARDASIL 9 (Table 12).
One month following the last dose of the assigned regimen, between 97.9% and 100% of subjects
across all groups became seropositive for antibodies against the 9 vaccine HPV types (Table 12).
In the same study, in girls and boys 9 through 14 years old, GMTs at one month after the last vaccine
dose were numerically lower for some vaccine types after a 2-dose schedule than in girls 9 through 14
years old after a 3-dose schedule (HPV types 18, 31, 45, and 52 after 0, 6 months and HPV type 45 after
0, 12 months; Table 12). The clinical relevance of these findings is unknown.
Duration of immunity of a 2-dose schedule of GARDASIL 9 has not been established.” (opens the source at this quote in a new tab) Copy Flag
How was Gardasil 9 effectiveness inferred in males 16 to 26? Applies to Boys and men 16 through 26 years of age (Study 7)
How was Gardasil 9 effectiveness supported in women 27 to 45? Applies to Women 27 through 45 years of age (Study 9 immunobridging)
How effective was Gardasil, the predecessor of Gardasil 9, in women 16 to 26? Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9
“Table 6: Analysis of Efficacy of GARDASIL in the PPE* Population for Vaccine HPV Types
Disease Endpoints
GARDASIL
AAHS Control
% Efficacy (95% CI)
N
Number of
cases
N
Number of
cases
16- through 26-Year-Old Girls and Women†
HPV 16- or 18-related CIN 2/3 or AIS
8493
2
8464
112
98.2 (93.5, 99.8)
HPV 16- or 18-related VIN 2/3
7772
0
7744
10
100.0 (55.5, 100.0)
HPV 16- or 18-related VaIN 2/3
7772
0
7744
9
100.0 (49.5, 100.0)
HPV 6-, 11-, 16-, or 18-related CIN (CIN
1, CIN 2/3) or AIS
7864
9
7865
225
96.0 (92.3, 98.2)
HPV 6-, 11-, 16-, or 18-related Genital
Warts
7900
2
7902
193
99.0 (96.2, 99.9)
HPV 6- and 11-related Genital Warts
6932
2
6856
189
99.0 (96.2, 99.9)” (opens the source at this quote in a new tab) Copy Flag
Note: The label does not state the follow-up duration for the Table 6 trials.
How effective was Gardasil (predecessor vaccine) against genital and anal lesions in males 16-26? Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9
“16- through 26-Year-Old Boys and Men
External Genital Lesions HPV 6-, 11-, 16-, or 18-related
External Genital Lesions
1394
3
1404
32
90.6 (70.1, 98.2)
Condyloma
1394
3
1404
28
89.3 (65.3, 97.9)
PIN 1/2/3
1394
0
1404
4
100.0 (-52.1, 100.0)
HPV 6-, 11-, 16-, or 18-related Endpoint
AIN 1/2/3
194
5
208
24
77.5 (39.6, 93.3)
AIN 2/3
194
3
208
13
74.9 (8.8, 95.4)
AIN 1
Condyloma Acuminatum
Non-acuminate
194
194
194
4
0
4
208
208
208
16
6
11
73.0 (16.3, 93.4)
100.0 (8.2, 100.0)
60.4 (-33.5, 90.8)” (opens the source at this quote in a new tab) Copy Flag
Note: The label does not state the follow-up duration for the Table 6 trials.
How effective was Gardasil (predecessor vaccine) in women 27 to 45? Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9
“In the base study (median duration of follow-up of 3.5 years post-dose 3), the efficacy of GARDASIL
against the combined incidence of HPV 6-, 11-, 16-, and 18-related persistent infection, genital warts,
VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia (any grade CIN), AIS and cervical cancer in
the PPE population was 87.7% (95% CI: 75.4%, 94.6%). The efficacy estimate for the combined endpoint
was driven primarily by prevention of persistent infection. The efficacy of GARDASIL against the
combined incidence of HPV 6-, 11-, 16-, and 18-related genital warts or cervical dysplasia was 95.0%
(95% CI: 68.7%, 99.9%) in the PPE population. While no statistically significant efficacy was
demonstrated for GARDASIL in the base study for prevention of cervical intraepithelial neoplasia grades
2 and 3 (CIN 2/3), adenocarcinoma in situ (AIS) or cervical cancer related to HPV types 16 and 18, there
was 1 case of CIN 2/3 observed in the GARDASIL group and 5 cases in the placebo group. The CIN 2
case in the GARDASIL group tested positive by PCR for HPV 16 and HPV 51.” (opens the source at this quote in a new tab) Copy Flag
How was Gardasil (predecessor vaccine) effectiveness inferred in men 27 to 45? Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9
“Effectiveness of GARDASIL in men 27 through 45 years of age is inferred from efficacy data in women
27 through 45 years of age as described above and supported by immunogenicity data from a clinical trial
in which 150 men, 27 through 45 years of age, received a 3-dose regimen of GARDASIL (0, 2, 6 months).
A cross-study analysis of per-protocol immunogenicity populations compared Month 7 anti-HPV 6, 11, 16,
and 18 GMTs of these 27- through 45-year-old men (Study A) to those of 16- through 26-year old boys
and men (Study B) in whom efficacy of GARDASIL had been established (see Table 6). GMT ratios
(Study A/Study B) for HPV 6, 11, 16, and 18 were 0.82 (95%CI: 0.65, 1.03), 0.79 (95%CI: 0.66, 0.93),
0.91 (95%CI: 0.72, 1.13), and 0.74 (95%CI: 0.59, 0.92), respectively.” (opens the source at this quote in a new tab) Copy Flag
Long-term results What did 10-year follow-up show after Gardasil 9 in ages 9 to 15? Applies to Girls and boys 9 through 15 years of age
“In an extension study of individuals in Study 2, 971 girls and 301 boys 9 through 15 years of age at
enrollment who received a 3-dose regimen of GARDASIL 9 were actively followed from age 16 onwards
for endpoint cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related persistent infection and
disease. For girls, disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-
related CIN (any grade), AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer and vaginal
cancer. For boys, the disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and
58-related PIN, external genital warts, penile cancer, perineal cancer and perianal cancer.
Analysis of the per-protocol population included 872 girls and 262 boys who completed the
GARDASIL 9 vaccination series within one year, were seronegative to the relevant HPV type at initiation
of the vaccination series and had not initiated sexual activity prior to receiving the third dose of
GARDASIL 9. The median follow-up from the last dose of vaccine was 10.0 years with a range of 3.0 to
11.0 years in girls 9 through 15 years of age and 9.9 years with a range of 3.0 to 10.6 years in boys 9
through 15 years of age.
In girls, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related CIN 2/3, AIS, VIN, VaIN,
external genital warts, cervical cancer, vulvar cancer or vaginal cancer were observed over a total of
4,576.1 person-years at risk. One case of CIN1 that tested positive for HPV 16, 39 and 59 by PCR was
observed. In boys, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external
genital warts, penile cancer, perineal cancer or perianal cancer were observed over a total of 1,278.6
person-years at risk.” (opens the source at this quote in a new tab) Copy Flag
“In an extension study of individuals in Study 2, among girls and boys 9 through 15 years of age at
enrollment (range of 494 to 525 subjects with evaluable data across HPV types) and followed for 10 years
post dose 3, anti-HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 GMTs as measured by cLIA were decreased
compared with corresponding values at one-month post-dose 3. The proportion of seropositive subjects
ranged from 99.6% to 100% at one month post-dose 3 and from 81.3% to 97.7% at 10 years post-dose 3,
depending on HPV type.” (opens the source at this quote in a new tab) Copy Flag
What did long-term follow-up of Gardasil (predecessor vaccine) show? Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9
“An extension study in girls and women 16 through 23 years of age used national health care registries
in Denmark, Iceland, Norway, and Sweden to monitor endpoint cases of HPV 6-, 11-, 16-, or 18-related
CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal cancer among 2,650 girls and women 16
through 23 years of age at enrollment who were randomized to vaccination with GARDASIL. An interim
analysis of the per-protocol effectiveness population included 1,902 subjects who completed the
GARDASIL vaccination series within one year, were naïve to the relevant HPV type through 1 month
post-dose 3, had no protocol violations, and had follow-up data available. The median follow-up from the
first dose of vaccine was 6.7 years with a range of 2.8 to 8.4 years. At the time of interim analysis, no
cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, cervical cancer, vulvar cancer, or vaginal
cancer were observed over a total of 5,765 person-years at risk.” (opens the source at this quote in a new tab) Copy Flag
“An extension study of 614 girls and 565 boys 9 through 15 years of age at enrollment who were
randomized to vaccination with GARDASIL actively followed subjects for endpoint cases of HPV 6-, 11-,
16-, or 18-related persistent infection, CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer,
vaginal cancer, and external genital lesions from the initiation of sexual activity or age 16 onwards. An
interim analysis of the per-protocol effectiveness population included 246 girls and 168 boys who
completed the GARDASIL vaccination series within one year, were seronegative to the relevant HPV
type at initiation of the vaccination series, and had not initiated sexual activity prior to receiving the third
dose of GARDASIL. The median follow-up from the first dose of vaccine was 7.2 years with a range of
0.5 to 8.5 years. At the time of interim analysis, no cases of persistent infection of at least 12 months’
duration and no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, VIN, VaIN, cervical
cancer, vulvar cancer, vaginal cancer, or external genital lesions were observed over a total 1,105
person-years at risk. There were 4 cases of HPV 6-, 11-, 16-, or 18-related persistent infection of at least
6 months’ duration, including 3 cases related to HPV 16 and 1 case related to HPV 6, none of which
persisted to 12 months’ duration.” (opens the source at this quote in a new tab) Copy Flag